---
reference_id: "PMID:29066163"
title: "Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study."
authors:
- Howard JF Jr
- Utsugisawa K
- Benatar M
- Murai H
- Barohn RJ
- Illa I
- Jacob S
- Vissing J
- Burns TM
- Kissel JT
- Muppidi S
- Nowak RJ
- "O'Brien F"
- Wang JJ
- Mantegazza R
- REGAIN Study Group
journal: Lancet Neurol
year: '2017'
doi: 10.1016/S1474-4422(17)30369-1
content_type: abstract_only
---

# Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
**Authors:** Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R, REGAIN Study Group
**Journal:** Lancet Neurol (2017)
**DOI:** [10.1016/S1474-4422(17)30369-1](https://doi.org/10.1016/S1474-4422(17)30369-1)

## Content

1. Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1.
Epub  2017 Oct 20.

Safety and efficacy of eculizumab in anti-acetylcholine receptor 
antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, 
randomised, double-blind, placebo-controlled, multicentre study.

Howard JF Jr(1), Utsugisawa K(2), Benatar M(3), Murai H(4), Barohn RJ(5), Illa 
I(6), Jacob S(7), Vissing J(8), Burns TM(9), Kissel JT(10), Muppidi S(11), Nowak 
RJ(12), O'Brien F(13), Wang JJ(13), Mantegazza R(14); REGAIN Study Group.

Collaborators: Mazia CG, Wilken M, Ortea C, Saba J, Rugiero M, Bettini M, Vidal 
G, Garcia AD, Lamont P, Leong WK, Boterhoven H, Fyfe B, Roberts L, Jasinarachchi 
M, Willlems N, Wanschitz J, Löscher W, De Bleecker J, Van den Abeele G, de 
Koning K, De Mey K, Mercelis R, Wagemaekers L, Mahieu D, Van Damme P, Smetcoren 
C, Stevens O, Verjans S, D'Hondt A, Tilkin P, Alves de Siqueira Carvalho A, 
Hasan R, Dias Brockhausen I, Feder D, Ambrosio D, Melo AP, Rocha R, Rosa B, 
Veiga T, Augusto da Silva L, Gonçalves Geraldo J, da Penha Morita Ananias M, 
Nogueira Coelho E, Paiva G, Pozo M, Prando N, Dada Martineli Torres D, Fernanda 
Butinhao C, Coelho E, Renata Cubas Volpe L, Duran G, Gomes da Silva TC, Otavio 
Maia Gonçalves L, Pazetto LE, Souza Duca L, Suriane Fialho TA, Gheller Friedrich 
MA, Guerreiro A, Mohr H, Pereira Martins M, da Cruz Pacheco D, Macagnan AP, de 
Cassia Santos A, Bulle Oliveira AS, Amaral de Andrade AC, Annes M, Cavalcante 
Lino V, Pinto W, Miranda C, Carrara F, Souza I, Genge A, Massie R, Campbell N, 
Bril V, Katzberg H, Soltani M, Ng E, Siddiqi Z, Phan C, Blackmore D, Vohanka S, 
Bednarik J, Chmelikova M, Cierny M, Toncrova S, Junkerova J, Kurkova B, 
Reguliova K, Zapletalova O, Pitha J, Novakova I, Tyblova M, Wolfova M, Jurajdova 
I, Andersen H, Harbo T, Vinge L, Mogensen A, Højgaard J, Witting N, Autzen AM, 
Pedersen J, Färkkilä M, Atula S, Nyrhinen A, Erälinna JP, Laaksonen M, Oksaranta 
O, Eriksson J, Harrison T, Desnuelle C, Sacconi S, Soriani MH, Decressac S, 
Moutarde J, Lahaut P, Solé G, Le Masson G, Wielanek-Bachelet AC, Gaboreau M, 
Moreau C, Wilson A, Vial C, Bouhour F, Gervais-Bernard H, Merle H, Hourquin C, 
Lacour A, Outteryck O, Vermersch P, Zephir H, Millois E, Deneve M, Deruelle F, 
Schoser B, Wenninger S, Stangel M, Alvermann S, Gingele S, Skripuletz T, Suehs 
KW, Trebst C, Fricke K, Papagiannopoulos S, Bostantzopoulou S, Vlaikidis N, 
Zampaki M, Papadopoulou N, Mitsikostas DD, Kasioti E, Mitropoulou E, 
Charalambous D, Rozsa C, Horvath M, Lovas G, Matolcsi J, Szabo G, Szabadosne B, 
Vecsei L, Dezsi L, Varga E, Konyane M, Gross B, Azrilin O, Greenbereg N, Bali 
Kuperman H, Antonini G, Garibaldi M, Morino S, Troili F, Di Pasquale A, Filla A, 
Costabile T, Marano E, Sacca F, Marsil A, Puorro G, Maestri Tassoni M, De Rosa 
A, Bonanno S, Antozzi C, Maggi L, Campanella A, Angelini C, Cudia P, Pegoraro V, 
Pinzan E, Bevilacqua F, Orrico D, Bonifati DM, Evoli A, Alboini PE, D'Amato V, 
Iorio R, Inghilleri M, Fionda L, Frasca V, Giacomelli E, Gori M, Lopergolo D, 
Onesti E, Gabriele M, Patti F, Salvatore Caramma A, Messina S, Reggio E, Caserta 
C, Uzawa A, Kanai T, Mori M, Kaneko Y, Kanzaki A, Kobayashi E, Masaki K, Matsuse 
D, Matsushita T, Uehara T, Shimpo M, Jingu M, Kikutake K, Nakamura Y, Sano Y, 
Nagane Y, Kamegamori I, Fujii Y, Futono K, Tsuda T, Saito Y, Suzuki H, Morikawa 
M, Samukawa M, Kamakura S, Shiraishi H, Mitazaki T, Motomura M, Mukaino A, 
Yoshimura S, Asada S, Kobashikawa T, Koga M, Maeda Y, Takada K, Takada MT, 
Yamashita Y, Yoshida S, Suzuki Y, Akiyama T, Narikawa K, Tsukita K, Meguro F, 
Fukuda Y, Sato M, Matsuo H, Fukudome T, Gondo Y, Maeda Y, Nagaishi A, Nakane S, 
Okubo Y, Okumura M, Funaka S, Kawamura T, Makamori M, Takahashi M, Hasuike T, 
Higuchi E, Kobayashi H, Osakada K, Taichi N, Tsuda E, Hayashi T, Hisahara S, 
Imai T, Kawamata J, Murahara T, Saitoh M, Shimohama S, Suzuki S, Yamamoto D, 
Konno S, Imamura T, Inoue M, Murata M, Nakazora H, Nakayama R, Ikeda Y, Ogawa M, 
Shirane M, Kanda T, Kawai M, Koga M, Ogasawara J, Omoto M, Sano Y, Arima H, 
Fukui S, Shimose S, Shinozaki H, Watanabe M, Yoshikawa C, van der Kooi A, de 
Visser M, Gibson T, Maessen J, de Baets M, Faber C, Keijzers MJ, Miesen M, 
Kostera-Pruszczyk A, Kaminska A, Kim BJ, Lee CN, Koo YS, Seok HY, Kang HN, Ra H, 
Kim BJ, Cho EB, Lee H, Min JH, Seok J, Koh DY, Kwon J, Lee J, Park S, Hong YH, 
Lim JS, Kim M, Kim SM, Kim YH, Lee HS, Shin HY, Hwang EB, Shin M, Sazonov D, 
Yarmoschuk A, Babenko L, Malkova N, Melnikova A, Korobko D, Kosykh E, Pokhabov 
D, Nesterova Y, Abramov V, Balyazin V, Casasnovas Pons C, Alberti Aguilo M, 
Homedes-Pedret C, Palacios NJ, Lazaro A, Diez Tejedor E, Fernandez-Fournier M, 
Lopez Ruiz P, Rodriguez de Rivera FJ, Salvado Figueras M, Gamez J, Salvado M, 
Cortes Vicente E, Diaz-Manera J, Querol Gutierrez L, Rojas Garcia R, Vidal N, 
Arribas-Ibar E, Piehl F, Hietala A, Bjarbo L, Lindberg C, Jons D, Andersson B, 
Sengun I, Ozcelik P, Tuga C, Ugur M, Boz C, Altiparmak D, Gazioglu S, Ozen Aydin 
C, Erdem-Ozdamar S, Bekircan-Kurt CE, Yilmaz E, Acar NP, Caliskan Y, Efendi H, 
Aydinlik S, Cavus H, Semiz C, Tun O, Terzi M, Dogan B, Onar MK, Sen S, Cavdar 
TK, Norwood F, Dimitriou A, Gollogly J, Mahdi-Rogers M, Seddigh A, Maier G, 
Sohail F, Sathasivam S, Arndt H, Davies D, Watling D, Rivner M, Hartmann JE, 
Quarles B, Smalley N, Amato A, Cochrane T, Salajegheh M, Roe K, Amato K, Toska 
S, Wolfe G, Silvestri N, Patrick K, Zakalik K, Katz J, Miller R, Engel M, 
Bravver E, Brooks B, Plevka S, Burdette M, Sanjak M, Kramer M, Nemeth J, 
Schommer C, Juel V, Guptill J, Hobson-Webb L, Beck K, Carnes D, Loor J, Anderson 
A, Lange D, Agopian E, Goldstein J, Manning E, Kaplan L, Holzberg S, Kassebaum 
N, Pascuzzi R, Bodkin C, Kincaid J, Snook R, Guinrich S, Micheels A, Chaudhry V, 
Corse A, Mosmiller B, Ho D, Srinivasan J, Vytopil M, Ventura N, Scala S, Carter 
C, Donahue C, Herbert C, Weiner E, McKinnon J, Haar L, McKinnon N, Alcon K, 
Daniels K, Sattar N, Jeffery D, McKenna K, Guidon A, David W, Dheel C, 
Levine-Weinberg M, Nigro C, Simpson E, Appel SH, Lai E, Lay L Jr, Pleitez M, 
Halton S, Faigle C, Thompson L, Sivak M, Shin S, Bratton J, Jacobs D, Brown G, 
Bandukwala I, Brown M, Kane J, Blount I, Freimer M, Hoyle JC, Agriesti J, Khoury 
J, Marburger T, Kaur H, Dimitrova D, Mellion M, Sachs G, Crabtree B, Keo R, 
Perez EK, Taber S, Gilchrist J, Andoin A, Darnell T, Goyal N, Sakamuri S, So YT, 
Welsh LW, Bhavaraju-Sanka R, Tobon Gonzalez A, Jones F, Saklad A, Nations S, 
Trivedi J, Hopkins S, Kazamel M, Alsharabati M, Lu L, Mumfrey-Thomas S, Woodall 
A, Richman D, Butters J, Lindsay M, Mozaffar T, Cash T, Goyal N, Roy G, Mathew 
V, Maqsood F, Minton B, Jones HJ, Rosenfeld J, Garcia R, Garcia S, Echevarria L, 
Pulley M, Aranke S, Berger AR, Shah J, Shabbir Y, Smith L, Varghese M, Gutmann 
L, Gutmann L, Swenson A, Olalde H, Hafer-Macko C, Kwan J, Zilliox L, Callison K, 
DiSanzo B, Naunton K, Bilsker M, Sharma K, Reyes E, Cooley A, Michon SC, Steele 
J, Karam CK, Chopra M, Bird S, Kaufman J, Gallatti N, Vu T, Katzin L, McClain T, 
Harvey B, Hart A, Huynh K, Beydoun S, Chilingaryan A, Droker B, Lin F, Shah A, 
Tran A, Akhter S, Malekniazi A, Tandan R, Hehir M, Waheed W, Lucy S, Weiss M, 
Distad J, Downing S, Strom S, Lisak R, Bernitsas E, Khan O, Kumar Sriwastava S, 
Tselis A, Jia K, Bertorini T, Arnold T, Henderson K, Pillai R, Liu Y, Wheeler L, 
Hewlett J, Vanderhook M, Dicapua D, Keung B, Kumar A, Patwa H, Robeson K, Nye J, 
Vu H.

Author information:
(1)Department of Neurology, University of North Carolina, Chapel Hill, NC, USA. 
Electronic address: howardj@neurology.unc.edu.
(2)Department of Neurology, Hanamaki General Hospital, Hanamaki, Japan.
(3)Department of Neurology, University of Miami Miller School of Medicine, 
Miami, FL, USA.
(4)Department of Neurology, International University of Health and Welfare, 
Narita, Japan.
(5)Department of Neurology, University of Kansas Medical Center, Kansas City, 
KA, USA.
(6)Neurology Department, Hospital Sant Pau, Universitat Autònoma Barcelona, 
Barcelona, Spain.
(7)Queen Elizabeth Neuroscience Centre, Wellcome Trust Clinical Research 
Facility, University Hospitals of Birmingham, Birmingham, UK.
(8)Rigshospitalet, Department of Neurology, University of Copenhagen, 
Copenhagen, Denmark.
(9)Department of Neurology, University of Virginia Health System, 
Charlottesville, VA, USA.
(10)Department of Neurology, Ohio State University, Columbus, OH, USA.
(11)Department of Neurology and Neurosciences, Stanford University School of 
Medicine, Stanford, CA, USA.
(12)Department of Neurology, Yale University School of Medicine, New Haven, CT, 
USA.
(13)Alexion Pharmaceuticals, New Haven, CT, USA.
(14)Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Erratum in
    Lancet Neurol. 2017 Dec;16(12):954. doi: 10.1016/S1474-4422(17)30377-0.

Comment in
    Lancet Neurol. 2017 Dec;16(12):947-948. doi: 10.1016/S1474-4422(17)30363-0.
    Lancet Neurol. 2018 Mar;17(3):204-205. doi: 10.1016/S1474-4422(18)30037-1.
    Lancet Neurol. 2018 Mar;17(3):205-206. doi: 10.1016/S1474-4422(18)30036-X.

BACKGROUND: Complement is likely to have a role in refractory generalised 
myasthenia gravis, but no approved therapies specifically target this system. 
Results from a phase 2 study suggested that eculizumab, a terminal complement 
inhibitor, produced clinically meaningful improvements in patients with 
anti-acetylcholine receptor antibody-positive refractory generalised myasthenia 
gravis. We further assessed the efficacy and safety of eculizumab in this 
patient population in a phase 3 trial.
METHODS: We did a phase 3, randomised, double-blind, placebo-controlled, 
multicentre study (REGAIN) in 76 hospitals and specialised clinics in 17 
countries across North America, Latin America, Europe, and Asia. Eligible 
patients were aged at least 18 years, with a Myasthenia Gravis-Activities of 
Daily Living (MG-ADL) score of 6 or more, Myasthenia Gravis Foundation of 
America (MGFA) class II-IV disease, vaccination against Neisseria meningitides, 
and previous treatment with at least two immunosuppressive therapies or one 
immunosuppressive therapy and chronic intravenous immunoglobulin or plasma 
exchange for 12 months without symptom control. Patients with a history of 
thymoma or thymic neoplasms, thymectomy within 12 months before screening, or 
use of intravenous immunoglobulin or plasma exchange within 4 weeks before 
randomisation, or rituximab within 6 months before screening, were excluded. We 
randomly assigned participants (1:1) to either intravenous eculizumab or 
intravenous matched placebo for 26 weeks. Dosing for eculizumab was 900 mg on 
day 1 and at weeks 1, 2, and 3; 1200 mg at week 4; and 1200 mg given every 
second week thereafter as maintenance dosing. Randomisation was done centrally 
with an interactive voice or web-response system with patients stratified to one 
of four groups based on MGFA disease classification. Where possible, patients 
were maintained on existing myasthenia gravis therapies and rescue medication 
was allowed at the study physician's discretion. Patients, investigators, staff, 
and outcome assessors were masked to treatment assignment. The primary efficacy 
endpoint was the change from baseline to week 26 in MG-ADL total score measured 
by worst-rank ANCOVA. The efficacy population set was defined as all patients 
randomly assigned to treatment groups who received at least one dose of study 
drug, had a valid baseline MG-ADL assessment, and at least one post-baseline 
MG-ADL assessment. The safety analyses included all randomly assigned patients 
who received eculizumab or placebo. This trial is registered with 
ClinicalTrials.gov, number NCT01997229.
FINDINGS: Between April 30, 2014, and Feb 19, 2016, we randomly assigned and 
treated 125 patients, 62 with eculizumab and 63 with placebo. The primary 
analysis showed no significant difference between eculizumab and placebo 
(least-squares mean rank 56·6 [SEM 4·5] vs 68·3 [4·5]; rank-based treatment 
difference -11·7, 95% CI -24·3 to 0·96; p=0·0698). No deaths or cases of 
meningococcal infection occurred during the study. The most common adverse 
events in both groups were headache and upper respiratory tract infection (ten 
[16%] for both events in the eculizumab group and 12 [19%] for both in the 
placebo group). Myasthenia gravis exacerbations were reported by six (10%) 
patients in the eculizumab group and 15 (24%) in the placebo group. Six (10%) 
patients in the eculizumab group and 12 (19%) in the placebo group required 
rescue therapy.
INTERPRETATION: The change in the MG-ADL score was not statistically significant 
between eculizumab and placebo, as measured by the worst-rank analysis. 
Eculizumab was well tolerated. The use of a worst-rank analytical approach 
proved to be an important limitation of this study since the secondary and 
sensitivity analyses results were inconsistent with the primary endpoint result; 
further research into the role of complement is needed.
FUNDING: Alexion Pharmaceuticals.

Copyright © 2017 Elsevier Ltd. All rights reserved.

DOI: 10.1016/S1474-4422(17)30369-1
PMID: 29066163 [Indexed for MEDLINE]